The 2020 Shenzhen Biotech (BT) Industry Summit officially kicked off at the Shenzhen Convention and Exhibition Center in Futian District yesterday.
Zhong Nanshan, recipient of the Medal of the Republic and academician of the Chinese Academy of Engineering (CAE), and Zhang Boli, recipient of the national honorary title “People’s Hero” and academician of the CAE, each delivered a speech via online video at the summit.
Focusing on biomedical technology and safety, this year’s summit features a high-end dialogue, two keynote speeches, three project roadshows, four launching ceremonies, five roundtable discussions, six professional forums and more than 30 specialized speeches.
The activities cover such fields as biotechnology and innovative drugs, modernization of traditional Chinese medicine, high-end medical devices, pharmaceutical policies and regulations, pharmaceutical investment and financing and new infrastructure driven by BT + IT.
The summit, with participation of more than 500 people, brings together academicians of the Chinese Academy of Sciences and the CAE, renowned experts and scholars, industry leaders and senior executives of biomedical enterprises to exchange views on the development of the biomedical industry in Shenzhen and the Guangdong-Hong Kong-Macao Greater Bay Area.
Shenzhen released eight major public service platforms for the biomedical industry at the summit. The platforms cover the R&D and production of pharmaceuticals and medical devices and aim to boost the high-quality development of the biomedical industry in the city.
The summit also witnessed the signing of a tripartite strategic cooperation framework agreement among Shenzhen Municipal Development and Reform Commission, Shenzhen Municipal Market Supervision and Regulation Bureau and China State Institute of Pharmaceutical Industry.
As of the end of 2019, Shenzhen had established more than 300 innovative platforms in the field of biomedicine, over 20 of which are at the State level. Meanwhile, among the 11 Nobel laureate laboratories in Shenzhen, four focus on biomedicine.